Robert W. Baird reaffirmed their hold rating on shares of Laboratory Corporation of America Holdings (NYSE:LH) in a research note published on Sunday.

Several other analysts have also commented on LH. Barclays PLC boosted their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an overweight rating in a research note on Thursday, July 27th. Jefferies Group LLC reaffirmed a hold rating and issued a $170.00 price target (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a research note on Wednesday, September 13th. BidaskClub lowered Laboratory Corporation of America Holdings from a buy rating to a hold rating in a research note on Friday, June 9th. ValuEngine raised Laboratory Corporation of America Holdings from a hold rating to a buy rating in a research note on Wednesday, September 6th. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $180.00 price target (up previously from $175.00) on shares of Laboratory Corporation of America Holdings in a research note on Monday, September 11th. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $164.00.

Laboratory Corporation of America Holdings (NYSE:LH) opened at 154.15 on Friday. Laboratory Corporation of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The company has a market capitalization of $15.69 billion, a PE ratio of 21.59 and a beta of 0.94. The company’s 50-day moving average price is $156.24 and its 200 day moving average price is $147.88.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a return on equity of 16.85% and a net margin of 7.57%. The company had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same quarter last year, the firm earned $2.36 EPS. Laboratory Corporation of America Holdings’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, equities research analysts anticipate that Laboratory Corporation of America Holdings will post $9.54 EPS for the current year.

WARNING: “Laboratory Corporation of America Holdings (LH) Rating Reiterated by Robert W. Baird” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/laboratory-corporation-of-america-holdings-lh-rating-reiterated-by-robert-w-baird/1576875.html.

In other news, CFO Glenn A. Eisenberg sold 5,968 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $159.46, for a total transaction of $951,657.28. Following the completion of the sale, the chief financial officer now owns 18,122 shares in the company, valued at $2,889,734.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Lisa J. Uthgenannt sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total value of $800,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 222,968 shares of company stock worth $34,980,922. Insiders own 0.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Laboratory Corporation of America Holdings by 2.3% during the second quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock worth $1,597,181,000 after acquiring an additional 231,600 shares during the last quarter. BlackRock Inc. raised its position in shares of Laboratory Corporation of America Holdings by 3,602.5% during the first quarter. BlackRock Inc. now owns 8,074,378 shares of the medical research company’s stock worth $1,158,430,000 after acquiring an additional 7,856,297 shares during the last quarter. State Street Corp raised its position in shares of Laboratory Corporation of America Holdings by 2.4% during the first quarter. State Street Corp now owns 4,639,813 shares of the medical research company’s stock worth $665,669,000 after acquiring an additional 109,170 shares during the last quarter. Boston Partners raised its position in shares of Laboratory Corporation of America Holdings by 4.8% during the second quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock worth $707,560,000 after acquiring an additional 210,138 shares during the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Laboratory Corporation of America Holdings by 2.0% during the second quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after acquiring an additional 54,100 shares during the last quarter. Institutional investors own 93.19% of the company’s stock.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Analyst Recommendations for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.